EWSR1::TFCP2-rearranged rhabdomyosarcoma of the skull bones: a clinical case and a literature review
Authors:
- Il'YA V. SidorovISIl'YA V. Sidorov
- A. S. SharlaiASA. S. Sharlai
- A. E. DruyADA. E. Druy
- A. V. PanferovaAPA. V. Panferova
- R. Kh. AbasovRAR. Kh. Abasov
- E. I. ChechevECE. I. Chechev
- D. V. ShevtsovDSD. V. Shevtsov
- I. N. VorozhtsovIVI. N. Vorozhtsov
- N. S. GrachevNGN. S. Grachev
- P. E. TrakhtmanPTP. E. Trakhtman
- D. M. KonovalovDKD. M. Konovalov
Open Access
- 13 December 2025
- journal article
- Published by Science for Children Foundation in Pediatric Hematology/Oncology and Immunopathology
- Vol. 24 (3) , 126-135
Abstract
Introduction. Rhabdomyosarcoma with EWSR1::TFCP2 rearrangement is a rare type of tumor with myogenic differentiation, characterized by an aggressive clinical course and difficulties in diagnosis. Our literature review highlights its key features: a predominance of craniofacial localization, an extremely unfavorable prognosis, and frequent aberrant immunophenotypic patterns. Particular attention is paid to the heterogeneity of tumors with myogenic differentiation, which include a wide range of entities with various genetic abnormalities. This calls into question the traditional diagnostic criteria for rhabdomyosarcoma and require their revision, given the lack of standardized therapy and the complexity of differential diagnosis. Clinical case. Here, we present a clinical case of rhabdomyosarcoma with EWSR1::TFCP2 rearrangement in a 12-year-old girl with primary involvement of the skull base. The tumor showed aggressive growth with the involvement of sphenoid and latticed bones and intracranial spread. Histological examination revealed an epithelioid spindle cell tumor invading bone tissue and a myogenic immunophenotype with the expression of pan-cytokeratin. The diagnosis was confirmed by FISH and high-throughput RNA sequencing, which verified the presence of EWSR1::TFCP2 chimeric transcript. Conclusion. The lack of standardized therapy and the difficulty of differential diagnosis underscore the need for further research to improve understanding, classification, and treatment of this type of rhabdomyosarcoma.Keywords
This publication has 16 references indexed in Scilit:
- Epithelioid and spindle cell rhabdomyosarcoma with EWSR1::TFCP2 fusion mimicking metastatic lung cancer: A case report and literature reviewPathology - Research and Practice, 2023
- Fusion-driven Spindle Cell Rhabdomyosarcomas of Bone and Soft Tissue: A Clinicopathologic and Molecular Genetic Study of 25 CasesLaboratory Investigation, 2023
- Rhabdomyosarcoma with TFCP2 Rearrangement or Typical Co-expression of AE1/AE3 and ALK: Report of Three New Cases in the Head and Neck Region and Literature ReviewHead and Neck Pathology, 2022
- ZFP64::NCOA3 gene fusion defines a novel subset of spindle cell rhabdomyosarcomaGenes, Chromosomes and Cancer, 2022
- Spindle cell/sclerosing rhabdomyosarcoma with DCTN1::ALK fusion: broadening the molecular spectrum with potential therapeutic implicationsVirchows Archiv, 2022
- Recurrent MEIS1-NCOA2/1 fusions in a subset of low-grade spindle cell sarcomas frequently involving the genitourinary and gynecologic tractsLaboratory Investigation, 2021
- Epithelioid and spindle cell rhabdomyosarcoma with FUS-TFCP2 or EWSR1-TFCP2 fusion: report of two casesVirchows Archiv, 2020
- FET(EWSR1)-TFCP2 Rhabdomyosarcoma: An Additional Example of this Aggressive Variant with Predilection for the Gnathic BonesHead and Neck Pathology, 2020
- TFCP2/TFCP2L1/UBP1 transcription factors in cancerCancer Letters, 2018
- A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutationsNature Genetics, 2014